Achieve Life Sciences, Inc. Cash and Cash Equivalents, Fair Value Disclosure
Achieve Life Sciences, Inc. (ACHV) had Cash and Cash Equivalents, Fair Value Disclosure of $19.70 million as of 2016-09-30, per its 10-Q filed 2016-11-10.
Discontinued › Notes › Fair Value Disclosures
us-gaap:CashAndCashEquivalentsFairValueDisclosure · last filed 2016-11-10
- 2016-09-30: Cash and Cash Equivalents, Fair Value Disclosure $19.70M.
| Period end | Cash and Cash Equivalents, Fair Value Disclosure |
|---|---|
| 2016-09-30 | $19.70M 10-Q · filed 2016-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |